Murata and Michelin Co-develop RFID Module to Improve Tire Management Operations
13.12.2021 04:00:00 EET | Business Wire | Press release
Murata Manufacturing Co., Ltd. (TOKYO:6981) (ISIN:JP3914400001) has co-developed a new generation of RFID modules with Michelin that are embedded into tires. The robust passive RFID tags require no external power supply and will continue to operate while being driven on for extremely high mileages. This simple yet elegant technology delivers low cost and easy tire traceability throughout its entire lifespan, enabling the management of inventory logistics, aftermarket maintenance, and recycling operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211212005019/en/
RFID modules that are embedded into tires (Graphic: Business Wire)
“RFID technology is a key enabler to gain efficiency and optimise tire operations, but also to improve the customer experience while identifying tires and associating data. An embedded tag is the only way to identify tires, from the cradle to the grave, consistently,” said Mr. Jerôme Barrand, Michelin RFID program leader. “Thanks to a great collaboration with Murata, a new efficient and cost-effective solution has been developed, enabling Michelin to address a larger market. This new generation of RFID tags is already in more than four million Michelin tires. As the technology is also available, from now on, to any other tire manufacturer, this shall foster market adoption.”
Currently, Michelin uses the RFID tags in commercial vehicles, such as lorries, busses and passenger cars. Michelin is working towards expanding this roll out to 100% of the MICHELIN tires from 2024. Importantly, the company anticipates that key players in the market will embrace this technology for improved tire traceability.
“Murata will continue to improve technologies for innovative solutions and will contribute to tire management operations throughout its lifecycle and the enhancement of customer experience,” says Masamichi Ando, Senior Director of RFID Business Department at Murata.
Murata has extensive experience and knowledge of RF technology and downsizing. Improving the reliability compared to existing RFID tags while minimizing cost were critical factors when developing the tire embeddable RFID tag. Designed and manufactured by Murata, the RFID module is approximately the size of a grain of rice, measuring 1x1x6 mm. By inserting it into a simple spring antenna designed and manufactured by HANA Technologies, the RFID tag achieves the simplest communication architecture, enabling it to link to the tire ecosystem.
In addition to the supply of this RFID module, Murata will be able to offer its id-BridgeTM platform (RFID middleware), which processes and interprets the data transmitted from the tire embeddable RFID tag in conformance with ISO standards*.
For more information about the tire embeddable RFID tags, which are already in mass production, please visit: https://rfid.michelin.com/
*ISO is the International Organization for Standardization that issues international standards for various industries. ISO20910 specifies the general requirements and data structure for coding the tire embeddable RFID tag. ISO20912 specifies the test methods for validating the conformance of RFID enabled tires.
Murata in Brief
Murata Manufacturing Co., Ltd. is a worldwide leader in the design, manufacture and sale of ceramic-based passive electronic components & solutions, communication modules and power supply modules. Murata is committed to the development of advanced electronic materials and leading edge, multi-functional, high-density modules. The company has employees and manufacturing facilities throughout the world. For more information, visit Murata's website at www.murata.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211212005019/en/
Contact information
For more information, please contact:
Murata Manufacturing Co., Ltd.
Tomohiro Ueno, prsec_mmc@murata.com
Corporate Communications Department
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK ® and TRIKAFTA ® , Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 14:30:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported by clinical and/or in vitro data from 564 variants demonstrating response to ALYFTREK and 521 variants demonstrating response to TRIKAFTA. As such, approximately 800 more people with a clinical diagnosis of CF in the U.S. are now eligible for a medicine that treats the underlying cause of their disease for the first time. This extension means approxim
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 14:30:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooperative networks of CCTG, GI Cancer Trials in Australia and France’s Partenariat de Recherche en Oncologie Digestive (PRODIGE) consortium (including Unicancer, GERCOR and FFCD). The BATTMAN (CO.33) trial serves as the registrational-enablin
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 14:19:00 EEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 14:00:00 EEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
